NDAORALTABLET
Approved
Apr 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
19
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANRAFIA (atrasentan) is an oral small-molecule endothelin receptor antagonist approved by FDA on April 2, 2025. The exact therapeutic indication is not disclosed in available data, but atrasentan is a selective ETA receptor antagonist with established mechanisms in renal and cardiovascular disease. Patient selection and dosing strategy will depend on the approved indication and clinical trial outcomes.
Growth16.5 years to LOE
Recently approved product in early growth phase with no current competitive pressure, suggesting opportunity for brand establishment and rapid team scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (19)
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
Started Sep 2026
20 enrolled
IgA Nephropathy (IgAN)Immunoglobulin A Nephropathy (IgAN)
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Started Aug 2026
28 enrolled
Berger DiseaseBergers DiseaseIgA Nephropathy+3 more
IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
Started May 2026
80 enrolled
IgA Nephropathy
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Started Jul 2023
54 enrolled
IgA NephropathyImmunoglobulin A Nephropathy
Atrasentan in Patients With Proteinuric Glomerular Diseases
Started Mar 2021
103 enrolled
IgA NephropathyFocal Segmental GlomerulosclerosisAlport Syndrome+3 more
Worked on VANRAFIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.